Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

148 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.
Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Ninomiya JK, et al. Circulation. 2004 Jan 6;109(1):42-6. doi: 10.1161/01.CIR.0000108926.04022.0C. Epub 2003 Dec 15. Circulation. 2004. PMID: 14676144
New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.
Fedder DO, Koro CE, L'Italien GJ. Fedder DO, et al. Circulation. 2002 Jan 15;105(2):152-6. doi: 10.1161/hc0202.101971. Circulation. 2002. PMID: 11790693
The metabolic syndrome and schizophrenia: a review.
Meyer J, Koro CE, L'Italien GJ. Meyer J, et al. Int Rev Psychiatry. 2005 Jun;17(3):173-80. doi: 10.1080/09540260500071798. Int Rev Psychiatry. 2005. PMID: 16194788 Review.
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.
Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Malik S, et al. Circulation. 2004 Sep 7;110(10):1245-50. doi: 10.1161/01.CIR.0000140677.20606.0E. Epub 2004 Aug 23. Circulation. 2004. PMID: 15326067
Major CHD risk factors predominate among African-American women who are eligible for lipid-lowering drug therapy under the new ATP III guidelines.
Koro CE, L'italien GJ, Fedder DO. Koro CE, et al. Eur J Cardiovasc Prev Rehabil. 2004 Oct;11(5):376-81. doi: 10.1097/01.hjr.0000140715.17392.6d. Eur J Cardiovasc Prev Rehabil. 2004. PMID: 15616409
Primary prevention lipid-lowering drug therapy.
Fedder DO, Koro CE, L'Italien GJ. Fedder DO, et al. Circulation. 2002 Aug 13;106(7):e35-6; author reply e35-6. doi: 10.1161/01.cir.0000025828.88749.55. Circulation. 2002. PMID: 12176971 No abstract available.
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L, McQuade RD. Blonde L, et al. J Clin Psychiatry. 2008 May;69(5):741-8. doi: 10.4088/jcp.v69n0507. J Clin Psychiatry. 2008. PMID: 18435564 Clinical Trial.
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. L'Italien GJ, et al. J Clin Psychiatry. 2007 Oct;68(10):1510-6. doi: 10.4088/jcp.v68n1006. J Clin Psychiatry. 2007. PMID: 17960964
Prevalence and control of dyslipidemia among persons with diabetes in the United States.
Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, Chen RS, Wong ND. Jacobs MJ, et al. Diabetes Res Clin Pract. 2005 Dec;70(3):263-9. doi: 10.1016/j.diabres.2005.03.032. Diabetes Res Clin Pract. 2005. PMID: 15890427
Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome.
Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Wong ND, et al. Am J Cardiol. 2003 Jun 15;91(12):1421-6. doi: 10.1016/s0002-9149(03)00392-8. Am J Cardiol. 2003. PMID: 12804727
148 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback